Your browser doesn't support javascript.
loading
Epidural dexmedetomidine infusion for perioperative analgesia in patients undergoing abdominal cancer surgery: randomized trial.
Hetta, Diab Fuad; Fares, Khaled Mohamed; Abedalmohsen, Abualauon Mohamed; Abdel-Wahab, Amani Hassan; Elfadl, Ghada Mohammed Abo; Ali, Wesam Nashat.
Afiliación
  • Hetta DF; Anesthesia and Pain Management, South Egypt Cancer Institute, diabhetta25@gmail.com.
  • Fares KM; Anesthesia and Pain Management, South Egypt Cancer Institute, diabhetta25@gmail.com.
  • Abedalmohsen AM; Anesthesia and Intensive Care, Faculty of Medicine, Assuit University, Assuit, Egypt.
  • Abdel-Wahab AH; Anesthesia and Intensive Care, Faculty of Medicine, Assuit University, Assuit, Egypt.
  • Elfadl GMA; Anesthesia and Intensive Care, Faculty of Medicine, Assuit University, Assuit, Egypt.
  • Ali WN; Anesthesia and Intensive Care, Faculty of Medicine, Assuit University, Assuit, Egypt.
J Pain Res ; 11: 2675-2685, 2018.
Article en En | MEDLINE | ID: mdl-30464585
ABSTRACT

OBJECTIVE:

To assess the postoperative analgesic efficacy of epidural dexmedetomidine added to bupivacaine infusion for patients undergoing major abdominal cancer surgery.

METHODS:

Patients scheduled for major upper abdominal cancer surgery were allocated to group bupivacaine (n =32), in which patients received epidural bupivacaine infusion (6 mL/h bupivacaine 0.1%) for 48 hours postoperatively, or group bupivacaine + dexmedetomidine (n=32), in which patients received epidural dexmedetomidine added to bupivacaine infusion (6 mL/h of bupivacaine 0.1% + dexmedetomidine, 0.5 µg/mL) for 48 hours postoperatively. The cumulative morphine consumption, the time to first analgesic request, and the VAS pain score were evaluated.

RESULTS:

The cumulative morphine consumption was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine mean ± SD of 10.40±5.16 mg vs 23.23±8.37 mg with an estimated difference (95% CI) of -12.83 (-16.43, -9.24), (P<0.001). The time to the first analgesic demand was significantly delayed in group bupivacaine + dexmedetomidine compared with group bupivacaine median (IQR) of 6 (1.75, 8.25) h vs 1 (0, 4)h, (P<0.001). The mean collapsed over time of overall VAS pain scores at rest and movement was significantly reduced in group bupivacaine + dexmedetomidine compared with group bupivacaine mean ± SE of 1.6±0.08 vs 2.38±0.08 with an estimated difference (95% CI) of -0.8 (-1, -0.86), (P<0.001), and mean ± SE of 2.17±0.07 vs 3.25±0.07 with an estimated difference (95% CI) of -1.1 (-1.27, - 0.89), (P<0.001), respectively.

CONCLUSION:

Epidural infusion of dexmedetomidine added to bupivacaine for patients undergoing major abdominal cancer surgery significantly reduced morphine consumption, delayed time to first analgesic supplementation, and decreased pain intensity during the first 48 hours postoperatively without harmful derangement on hemodynamics.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2018 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Año: 2018 Tipo del documento: Article